Skip to content
Black Friday — 30% OFFFree shipping on orders of A$99 or more
  1. Home
  2. Recovery & Regeneration
  3. Trevogrumab 1mg
Recovery

Trevogrumab 1mg

Trevogrumab (REGN1033, SAR-391786) is a fully human monoclonal antibody engineered for high-affinity, selective neutralisation of myostatin (GDF-8), a TGF-beta superfamily ligand that functions as a primary negative regulator of skeletal muscle mass.

Presentation: Trevogrumab 1mg.

Select the required strength and pack size.

Illustrative packaging generated with AI.

Presentation
Original price was: A$194.95.Current price is: A$136.47.

Available on request in Australia

Ask an advisor
An advisor contacts you and the partner pharmacy checks whether and how it can proceed. A valid prescription, or an assessment through an authorised telemedicine service, may be required.
  • Partner pharmacy
  • Personal assistance
  • Discreet delivery
  • Presentation
    Trevogrumab 1mg

Shipping & Delivery

  • Normally dispatched within 24 hours of payment confirmation.
  • USPS Regular Shipping · A$11.95 · Approx. 3–5 business days
  • FedEx 2 Days Delivery · A$28.99 · Approx. 2 business days
  • FedEx Overnight Delivery · A$40.99 · Approx. 1 business day

For laboratory research only.

Not for human or veterinary use.

Composition and product details

Overview

Trevogrumab (REGN1033, SAR-391786) is a fully human monoclonal antibody engineered for high-affinity, selective neutralisation of myostatin (GDF-8), a TGF-beta superfamily ligand that functions as a primary negative regulator of skeletal muscle mass. Research interest centers on its specificity for myostatin without cross-reactivity to other ActRIIB-binding ligands such as activins or GDF-11.

Research applications include myostatin pathway antagonist research, antibody-based ligand neutralisation studies, and comparative ActRIIB pathway inhibitor pharmacology.

  • High Purity – 99% Purity Guaranteed
  • Independently Lab Tested
  • Research Grade Quality
  • For Laboratory Research Use Only

Molecular data on PubChem

Trevogrumab 1mg1 vial | KIT (10 vials)

Properties

Chemical Formula C6374H9884N1696O2018S46
Synonyms REGN-1033 (REGN1033), Anti-GDF8/Myostatin antibody, SAR-391786
CAS Number 1429201-24-0
PubChem CID 384585220
Available formats 1 vial · KIT (10 vials)
Shelf Life 36 months

Research

Trevogrumab is a monoclonal antibody studied for its high-affinity, selective binding to myostatin (GDF-8), neutralising its capacity to engage the activin receptor type IIB (ActRIIB) and downstream Smad2/3 signalling cascade that suppresses skeletal muscle hypertrophy pathways. Its specificity profile distinguishes it from broader-spectrum ActRIIB ligand traps (such as soluble ActRIIB-Fc fusion proteins), which neutralise myostatin alongside activins, GDF-11, and BMP-9/10, making trevogrumab a research tool for isolating myostatin-specific pathway contributions without confounding activin or BMP pathway effects. In vitro Smad2/3 reporter assays and rodent muscle-mass studies are standard experimental approaches for characterising trevogrumab’s neutralising potency and downstream functional effects. Independently third-party HPLC-tested; COA available per batch.

FAQ

How does Trevogrumab’s myostatin selectivity distinguish it from broad-spectrum ActRIIB ligand traps in research?

Trevogrumab is engineered as a highly specific anti-myostatin (GDF-8) antibody, binding myostatin directly to prevent its engagement of ActRIIB, with minimal cross-reactivity to other TGF-beta superfamily ligands. This contrasts with soluble ActRIIB-Fc fusion protein ligand traps, which sequester myostatin alongside activins, GDF-11, and BMP-9/10 indiscriminately.

For research questions requiring isolation of myostatin-specific pathway contributions — without confounding effects from co-inhibited activin or BMP signalling — trevogrumab’s selective mechanism is the appropriate experimental tool.

What assay formats are used to confirm Trevogrumab’s neutralizing potency against myostatin-induced signaling?

Cell-based Smad2/3 reporter assays — using myoblast cell lines such as C2C12 transfected with a Smad-responsive luciferase construct — are standard for quantifying trevogrumab’s capacity to block myostatin-induced Smad2/3 transcriptional activation in a dose-dependent manner, typically expressed as an IC50 or neutralising dose. Surface plasmon resonance (SPR) or other direct binding-affinity methods are used in parallel to characterise trevogrumab’s intrinsic binding kinetics (Kd, on/off rates) to recombinant myostatin independent of the cell-based functional readout.

What rodent model endpoints are used to evaluate Trevogrumab’s functional effects on skeletal muscle mass?

Rodent studies investigating myostatin pathway antagonists typically measure lean body mass and individual muscle wet weight (e.g. gastrocnemius, quadriceps) following a defined dosing period, alongside functional measures such as grip strength or treadmill exercise capacity. These studies often include muscle fiber cross-sectional area histology to confirm hypertrophy at the cellular level, and serum myostatin/antibody pharmacokinetic sampling to correlate systemic drug exposure with the magnitude of the observed muscle-mass phenotype.

Original price was: A$194.95.Current price is: A$136.47.